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ABSTRACT 
 
THE ADOPTION OF HARM REDUCTION BY ABSTINENCE PROGRAM STAFF: 
A QUALITATIVE ANALYSIS 
 
MAY 2016 
MORGAN COE, B.A., EARLHAM COLLEGE 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor David R. Buchanan 
 
 
Opioid overdose fatalities have quadrupled in the United States since the turn of the 
century, and are becoming increasingly recognized as a nationwide epidemic. While naloxone 
(narcan) has long been the standard treatment for overdose in clinical settings, it has not been 
issued to opioid users or their family members in the U.S. until relatively recently. As naloxone 
distribution and overdose training become more widespread, they are being incorporated into 
more and more abstinence-oriented settings including detoxes, halfway houses, and outpatient 
methadone and suboxone treatment programs. This qualitative study explored whether the staff 
at such programs found that training their patients to use naloxone was disruptive or 
controversial, and whether they found it difficult to reconcile these trainings’ basis in harm 
reduction with their personal and organizational philosophies about substance use and recovery. 
Ten subjects from Eastern and Central Massachusetts were interviewed about their experience 
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introducing naloxone to their patients under the aegis of the Massachusetts Department of Public 
Health’s Opioid Overdose Prevention Pilot Program, and their interviews were analyzed from a 
descriptive phenomenological perspective. This approach seeks to distill the essence of a 
phenomenon by analyzing the narratives of those who have experienced it, and has been found 
especially useful when exploring questions that have not yet been studied in depth. The analysis 
identified eleven recurring themes, grouped into four broad domains (What is overdose 
prevention training? What is narcan? What is harm reduction? What is the goal of treatment?). 
These themes suggested that while subjects overwhelmingly experienced naloxone distribution 
and overdose prevention training as positive additions to their workplace, this experience did not 
necessarily lead to more engagement with the broader concept of harm reduction. 
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CHAPTER I 
PROBLEM STATEMENT 
 
Opiate users around the world have been found to have a mortality rate between 10 and 
20 times that of the surrounding population (Hickman et al., 2003; Oppenheimer et al., 1994; 
Perucci et al. 1991). The single largest cause of that mortality is overdose, which accounted for 
26% of user deaths in Frischer’s (1993) Scottish study, 34% in Goldstein and Herrera’s (1995) 
New Mexico study, and over half in Hickman’s (2003) London study. In Portland, Oregon 
overdose was “a leading cause of death” in the year 1999 among all men aged 25–54 (Oxman 
et al. 2000). Just as disturbingly, Hall & Darke (1998) found a six-fold increase in Australian 
overdose mortality between 1979 and 1995. The Center for Disease Control and Prevention 
(CDC/NCHS, 2015) reported that from 1999 to 2014, the U.S. drug overdose fatality rate more 
than doubled (from 6.1 to 14.7 per 100,000 people), and the opioid overdose fatality rate more 
than quadrupled (from 1.4 to 5.6 per 100,000). However, not all overdoses result in death: 38% 
of Strang’s (1999) study participants had previously overdosed, as had 44% of Green’s (2008) 
and 48% of Ochoa’s (2001). The rate at which participants had witnessed another user’s (not 
necessarily fatal) overdose was considerably higher: 54% in Strang’s (1999) first study, 86% in 
Darke’s (1996), 95% in Tobin’s (2009), and 97.4% in Strang’s (2000) later study. Clearly the 
prevalence and potential consequences of opiate overdose represent significant public health 
concerns, and perhaps one growing more serious with time. In 2014, 1.9 million Americans 
suffered from prescription painkiller addiction, and approximately 586,000 were using heroin 
(SAMHSA, 2015) 
There are many ways to decrease the likelihood and impact of opiate overdose. These 
options include: discouraging opiate use and increasing treatment and detox options, 
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decreasing concomitant risk factors (such as concurrent alcohol or benzodiazepine use) among 
opiate users, improving hospital and ambulance response to overdose, encouraging opiate 
users to adopt non-injection methods of opiate intake, providing safer injection facilities with 
medical staff, increasing the availability of maintenance treatment for opiate addicts, and 
providing take-home naloxone to opiate users (Darke & Hall, 2003; Sporer, 1999). While each 
of these options has certain advantages and disadvantages, the research proposed here focuses 
on of the newest and least well-studied alternative—providing take-home naloxone to opiate 
users. 
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CHAPTER II 
BACKGROUND 
 
Naloxone has been used as an effective treatment for opiate overdose in clinical 
settings since the early 1970s (World Health Organization, 1993). It functions as an opiate 
antagonist, blocking the drug’s effects for a typical duration of 45-90 minutes. It takes effect 
within 1-2 minutes at the most, and is considered to have only a very small chance of adverse 
effects in patients (Baca & Grant, 2005; Galea et al., 2006; Kerr et al., 2008; Sporer, 1999). 
Although naloxone is the standard treatment for overdose, it has not been issued to opiate users 
(or their family members) for use outside of medical facilities until relatively recently. This 
practice was begun as a component of European and Australian anti-overdose interventions in 
the mid 90s, and was first adopted in the United States in 2001, when the San Francisco 
Department of Public Health sponsored a pilot research program. In the same year, the state of 
New Mexico implemented laws that freed physicians and private citizens from the legal 
liabilities involved in having a drug prescribed to one person with the expectation that they 
would use it on someone else, or have it used on them by someone else (Sporer & Kral, 2007). 
There are currently naloxone training and distribution programs active in at least 30 U.S. 
states, including Massachusetts (Wheeler et al., 2015). 
In 2009, the greater Boston area led the nation in yearly drug- and heroin-related 
emergency room admissions per 100,000 residents (SAMHSA, 2011), and since 2005 opioid 
overdoses have surpassed automobile accidents as a cause of death in Massachusetts (Walley 
et al., 2013). In 2007 there were 9.9 opiate-related deaths per 100,000 state residents, 
compared to 5.2 in 1999 and 1.6 in 1990. In addition, there were 47 non-fatal hospitalizations 
for every death, and the total cost for hospitalizations related to opioid dependence and 
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overdose exceeded $239 million in 2007 (BSAS, 2009). In response to these rising rates of 
fatal opiate overdose, the Massachusetts Department of Public Health created the Opioid 
Overdose Prevention Pilot Program (OOPPP, or “Narcan Pilot Program” colloquially) in order 
to implement and study the effects of providing Overdose Education and Naloxone 
Distribution (OEND) in 2006. The OOPPP works with existing treatment programs such as 
detoxes, inpatient treatment programs, and short- or long-term recovery housing, in order to 
provide training and naloxone to at-risk individuals and potential bystanders (BSAS, 2012; 
Doe-Simpkins et al, 2009). 
In a 2010 survey conducted by the Harm Reduction Coalition, the OOPPP was one of 
48 U.S. naloxone providers providing OEND at 188 sites (Wheeler et al., 2010). When the 
same agency conducted a similar survey in 2014, that number had risen to 136 programs 
serving 644 sites (Wheeler et al., 2015). Not only did the number of programs providing 
OEND nearly triple over this time span, the geographical area that they covered increased 
substantially as well: from 15 states and the District of Columbia in 2010 (Wheeler et al., 
2010) to 30 states and the District of Columbia in 2014 (Wheeler et al., 2015). In other words, 
this four-year span did not just see naloxone become more accessible in states that had already 
embraced OEND—it also saw OEND adopted in many states that had previously resisted it. 
All together, these programs have distributed an estimated 150,000 naloxone kits and have 
tracked over 26,000 opioid overdose reversals (Wheeler et al., 2015). 
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CHAPTER III 
LITERATURE REVIEW 
 
The concept of “harm reduction” has been applied to injection drug use in many ways, 
and encompasses a wide range of strategies. These include, but are not limited to, syringe 
exchange, street outreach, supervised injection facilities, promoting non-injection routes of drug 
administration, risk reduction education, “grass roots” organizing of drug-injecting peers, drug 
purity testing, and naloxone distribution (Ritter & Cameron, 2006). What these interventions 
have in common is that they aim primarily to reduce the harm associated with drug injection; 
while they may not exclude working towards (short- or long-term) abstinence or decreased use, 
these are not goals in and of themselves (Lenton & Single, 1998). 
There is not much published research on the ways that narcan-based overdose 
prevention has been incorporated into treatment and recovery settings, and a majority of 
published articles focus on naloxone distribution in syringe exchanges, by street outreach 
workers, and through peer recruitment channels. 
In their discussion of a Wisconsin counseling program serving primarily substance using 
women, Ackerson & Karoll (2005) report that that “incorporating a harm-reduction philosophy 
within a traditional abstinence-based agency setting” was challenging for staff, both from a 
clinical standpoint and in terms of collaborating with outside agencies who continued to adhere 
to a strict abstinence-oriented framework. However, in this case “harm reduction” is 
conceptualized primarily in terms of staff’s being open to helping clients work towards goals 
other than full sobriety, and accepting the possibility of relapse as part of the recovery 
process—there is no mention of taking active steps like providing naloxone to current or past 
opiate users. 
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In an email questionnaire, Hofschulte (2012) investigated Minnesota social workers’ 
attitudes towards harm reduction and towards substance users in order to determine whether 
positive or negative attitudes towards either or both were connected to the clinicians’ 
demographic characteristics, professional history, or self-perception. She found that positive 
attitudes towards harm reduction were associated with having worked with substance using 
populations, having been trained on substance use and addiction, and perceiving this training 
as adequate. On the other hand, only past training on substance use and addiction was 
associated with belief in the efficacy of harm reduction-based treatment. None of the 
measured factors were associated with positive or negative perceptions of substance users. 
Koutroulis (2000) conducted a small qualitative study that explored the ways that 
substance treatment staff understood and applied the concept of harm reduction. For the 
purposes of this research, “harm reduction” was conceptualized primarily in terms of staff’s 
being open to working towards goals other than full long-term abstinence, and willing to 
provide education and resources that support safer substance use. She described an ongoing 
tension between clients (who generally entered the program with the intention of ceasing 
substance use) and staff (who often felt that it was safest to assume that their clients would not 
be able to maintain abstinence). Some staff found it conceptually challenging to negotiate the 
gap between ideal (abstinence) and reality (expected relapse), and therefore saw harm 
reduction as a tool to be used when they judged a particular client to be at risk for relapse, or 
unlikely to contine attending their program. Others saw no conflict between harm reduction 
and abstinence, and consistently provided harm reduction information and counseling as part 
of their baseline treatment. As with Ackerson and Karoll (2005), there is no mention of 
providing naloxone to clients potentially at risk for opiate overdose. 
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Maxwell et al. (2006) describe a Chicago-area naloxone distribution program similar to 
the one implemented in Massachusetts, and report that it appeared to be effective: not only did 
it result in 319 reported overdose reversals from 2001 to 2006, but the local rate of fatal 
overdose declined during the first 3 years it was implemented after rising steadily for a decade. 
This program provided naloxone via outreach vans, at fixed sites, and through a telephone 
pager system, but did not contact opiate users in treatment or recovery settings. However, the 
authors strongly advocate for expanding overdose prevention training and naloxone 
distribution into detoxes. 
In their interviews with a treatment sample of methadone clinic patients who had little 
or no previous experience with naloxone, Strang et al. (1999) found strong support for 
naloxone distribution as a way to decrease overdose fatalities. While 70% of this population 
felt that distributing naloxone would be either a “good” or “very good” idea, only 13% felt that 
it would be a “bad idea. Within that dissenting minority, less than half of felt that it might 
encourage them to increase their opiate use. While this study did not address the views of 
methadone program staff, it does suggest that there may be substantial interest in naloxone 
among substance users who are in treatment or recovery. 
Using data collected by the OOPPP’s programs in Massachusetts, Walley et al. (2013) 
described the program’s success in training and enrolling nearly 1,000 opiate users from 
methadone treatment and detox settings, which resulted in 33 reported overdose reversals from 
2008 to 2010. These reversals were reported to staff by the trainees themselves after the fact, 
either when they returned for more naloxone, or when they were seeking other services from 
the OOPPP program that trained them. Therefore, this total would not count reversals 
performed by opiate users who had no subsequent contact with program staff—perhaps 
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because they stopped using, because they were able to obtain naloxone from other sources, or 
because they left the area. Furthermore, it is possible that even trainees who did return to an 
OOPPP program to get a naloxone refill might not have consistently reported overdose 
reversals. For instance, they may have felt obliged to “protect” the people or places involved, 
they may have believed that it was not their place to report the incident because they did not 
directly administer the naloxone, or they may have forgotten the incident (or decided that it 
“did not count”) because so much time had elapsed between the reversal and their next 
program contact. 
Walley et al. (2013) also outline five different ways that overdose prevention training 
and naloxone were being provided to detox and methadone treatment patients: 
1. Treatment program staff were certified to provide education and naloxone directly 
to their patients. 
2. Treatment programs hosted outside certified trainers to provide education 
and naloxone to their patients. 
3. Treatment program staff provided education, but referred their patients to one or 
more off-site programs in order to receive naloxone. 
4. OOPPP program staff conducted targeted outreach in order to provide 
education and naloxone to detox or methadone program patients. 
5. OOPPP program staff provided education and naloxone at sites not affiliated with 
treatment programs 
Of these categories, the first two will be especially relevant to this research project. 
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CHAPTER IV 
SIGNIFICANCE 
 
As narcan distribution becomes more accepted as an effective way to reduce opiate 
overdose fatalities, it seems likely that programs like OOPPP will expand. This is something 
that I observed firsthand while working at the Cambridge Needle Exchange—at times it seemed 
like the demand for narcan training was so high that the availability of certified training staff 
was the only limiting factor. While narcan appears to have been enthusiastically adopted as a 
life-saving strategy by state officials, harm reduction agencies, and opiate users themselves, 
there appears to be a lack of research and data on the ways that it has or has not been embraced 
by the staff of more traditional, recovery-oriented programs. 
This is significant because these programs offer a valuable opportunity to reach opiate 
users in an environment that is more structured than a typical street outreach or drop-in center 
contact. Most detox, inpatient treatment, and recovery housing programs require their patients 
to attend a regular schedule of groups and classes, and integrating OEND into this schedule 
would ensure that the trainers have a physical space in which to conduct demonstrations and 
enrollments, a set time in which to conduct the training, and a regular time and place for 
trainees to participate—all of which may be lacking in more informal training settings. 
Furthermore, recovery-oriented programs serve a broader demographic that includes individuals 
who have stopped or intend to stop using opiates (Koutrolis, 2000), and who may not choose to 
visit the social and physical settings where active users are more likely to be found. However, a 
lack of staff buy-in may hamper efforts to expand narcan training into these types of programs. 
Learning more about how these staff members assess the integration of narcan training into 
their programs could improve the situation in two ways: first, by revealing areas where further 
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training or resources would benefit them, and second, by suggesting ways that the narcan 
distribution and training staff could improve their relationships with the programs that host 
them. 
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CHAPTER V 
RESEARCH OBJECTIVES 
 
In my experience as a needle exchange staffer and program manager I have 
encountered a broad spectrum of reactions to the idea of offering naloxone training in 
substance treatment settings. These reactions influence the ease or difficulty with which the 
initial training may be scheduled, the amount of interest or disinterest with which staff 
participate in the training, the extent to which they do or do not encourage patients to attend 
patient trainings if they are offered, and the ease or difficulty of organizing further trainings, 
naloxone distribution, or other follow-up meetings. I decided to explore this issue further by 
conducting a study that addressed the following research questions: 
1. Was the integration of OEND into recovery-oriented programs disruptive or 
controversial? If so, why? 
2. Did recovery-oriented program staff find it difficult to reconcile the harm 
reduction philosophy underlying OEND with their personal and 
organizational philosophies around substance use and recovery? 
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CHAPTER VI 
METHODS 
 
This research project used a qualitative methodology, based on the principles of 
descriptive phenomenology. This approach seeks to distill the essence of a phenomenon by 
analyzing the description of individuals who have experienced it, and it has been found 
especially useful when the phenomenon of interest has not been previously studied, or has 
been only incompletely analzyed (Wojnar & Swanson, 2007). Since there is currently very 
little published research on the integration of narcan and overdose prevention into addiction 
treatment settings, the choice of descriptive phenomenology seemed appropriate here. This 
methodology is based on the assumption that “there are features to any lived experience that 
are common to all persons who have the experience” (Lopez & Willis, 2004, p.728), and this 
study will use the lived experience of addiction treatment program staff as a window to learn 
about the underlying phenomenon of integrating overdose prevention and harm reduction into 
recovery-oriented treatment programs. However, in light of the opiate overdose crisis facing 
many countries today, learning for its own sake is not the final goal of this study. Hopefully, 
its analysis will help to inform future research and program planning efforts as well—a goal to 
which descriptive phenomenology is well-suited (Wojnar & Swanson, 2007). 
The integration of OEND into addiction treatment settings is experienced by at least 
two distinct populations: the staff of the programs in question, and their patients. However, 
conducting ethically sound research with patients (many of whom also belong to other 
vulnerable populations) is beyond the scope of this project. Furthermore, the Massachusetts 
Department of Public Health and OOPPP indicated that they would not support my attempting 
such research at this time. Therefore, this study’s subject population consisted of treatment 
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program staff only. Furthermore, since descriptive phenomenology dictates that researchers 
learn about a phenomenon through those who have experienced it, this study restricted its 
sample to treatment program staff who had themselves experienced the integration of OEND 
into their programs. In other words, subjects were drawn from settings falling under the first 
two categories of Walley et al.’s taxonomy (2013)—those in which the treatment program 
staff were trained to provide OEND directly to their own patients, and those in which they 
hosted outside trainers from OOPPP programs. It excluded treatment programs that 
exclusively referred patients to other locations for narcan distribution, and where OOPPP 
programs conducted outreach or recruitment, but did not actually provide OEND. 
Since this study’s research questions both addressed the issue of whether the 
experience of OEND integration was a positive one, it  used a purposive deviant sampling 
strategy based on how smoothly OOPPP staff and trainers felt that the integration process 
went. This allowed the final analysis to incorporate perspectives from staff whose programs 
embraced OEND (on an operational level, at least), as well as those whose programs resisted 
it or found it logistically difficult to adopt. This approach allowed the study’s analysis to 
develop a broader and richer understanding of the phenomenon, to “uncover […] the 
boundaries of difference within [the] experience”, (Polkinghorne, 2005, p.141), and to 
“illuminate subtle but potentially important differences” (Barbour, 2001, p.1116) between the 
purposive sample’s sub-groups. 
Although ideal qualitative sample sizes cannot be computed the same way that 
quantitative ones can, there does appear to be a general consensus that descriptive 
phenomenological studies can obtain useful data from relatively small samples (Maggs-
Rapport, 2001; Omery, 1983). In fact, some research suggests that such studies may reach 
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saturation—the point at which adding more data does not help researchers to develop new 
categories, or to further refine the properties of those they have already identified—with 
sample sizes of a dozen or less (Guest et al., 2006; Starks & Trinidad, 2007). Morse (2000) 
states that studies with relatively narrow scopes may expect to reach saturation using smaller 
samples. With that in mind, this study’s planned sample size was to be ten individuals, 
interviewed one time apiece. Analysis of the interviews suggested that this was enough to 
achieve saturation: several important themes appeared in all or nearly all the interviews, and 
many themes were present in a solid majority of them. Even when themes encompassed 
different perspectives, there was enough overlap between the subjects’ experiences for them 
to confirm and complement one another. Based on this analysis, I would have expected that 
adding more data (without altering the study’s sampling or selection process, as discussed 
below) would have tended to confirm and reinforce the themes that were already appearing 
consistently. 
The sample was assembled as follows: each OOPPP program was asked to list the 
treatment settings in which it conducts OEND trainings or where it has trained local staff to 
conduct them, rating each one on a 1-3 scale according to how smoothly it integrated OEND. 
The scale was intended to highlight the positive and negative extremes of the potential subject 
pool, in accordance with purposive sampling practice: 
1. The program requested OEND and was supportive of OOPPP staff 
2. The program did not actively request OEND but was not resistant to it 
3. OOPPP staff had to reach out to the program several times before they agreed to 
host OEND, and/or found it challenging to collaborate with them 
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I then reached out to potential subjects in order to assemble a ten-person sample. The intent 
was to make sure that both extremes were represented in the study’s sample, so I attempted to 
include at least three staff from programs that were rated “1” on the scale above, and at least 
three from programs that were rated “3.” In practice, this was somewhat challenging as a 
majority of the contacts I was given by OOPPP staff fell under the first category, which made it 
difficult to schedule interviews with subjects from the second and third categories. In 
particular, only 3 programs were identified as “challenging,” one of which did not respond to 
participate, even after I made several attempts to contact them. Ultimately, the sample 
consisted of 7 subjects from “supportive” programs (category 1), 1 subject from a “neutral” 
program (category 2), and 2 subjects from “challenging” programs (category 3). This may 
represent a limitation of the study, and will be discussed at more length in a later section. 
 
Instrument 
This project’s data collection instrument was an open-ended interview protocol. It 
consisted of 11 main questions; follow-up prompts were sometimes used depending on the 
depth and detail of the subject’s initial answer. The questions were sequenced to begin with a 
background question, and then to proceed from concrete questions about the present, to 
concrete questions about the past, and finally to more reflective questions. 
 
 1. What kinds of experience have you had in the substance abuse and addiction field? 
 a) What positions have you held at [your program]? 
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 2. How do narcan trainings happen at your program? [If the answer does not appear to fit 
into the five categories outlined in Walley et al., 2013 and cited in the Literature Review 
section, subject will be asked to elaborate] 
 a) How does [your program’s] staff decide when to schedule a narcan training? 
 b) Which members of [your program’s] staff and patients go to these trainings? 
 3. What do the outside trainers do when they run a narcan training at [your program]? 
 4. What is your role when a narcan training happens at [your program]? 
 5. Think back to the time before [your program] started hosting narcan trainings. What 
made [your program] decide to start hosting narcan trainings? 
 a) What did you see as the pros and cons of narcan training before it started 
happening at [your program]? 
 b) What did you expect from the first narcan training at [your program]? 
 6. How did the first few narcan trainings go? 
 a) What concerns did [your program’s] staff have about those first few narcan 
trainings? 
 b) What benefits did they see in hosting narcan trainings? 
 c) How did your clients feel about those first few narcan trainings? 
 7. How are [your program’s] narcan trainings going these days? 
 a) How would you say [your program’s] staff feel about narcan training now? 
 b) How would you say your clients feel about narcan training now? 
 c) How have these trainings affected your program, either positively or 
negatively? 
 8. What are your goals when working with clients at [your program]? 
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 9. How does harm reduction relate to your work at [your program]? 
 10. Think about different kinds of harm reduction, like safer injection training, encouraging 
drug injectors to switch to non-injection use, methadone and suboxone treatment, needle 
exchange, safer injection rooms, or drug decriminalization. 
 a) How do you feel about these things? 
 b) What differences do you see between them? 
 c) Which ones would you refer your clients to? 
 11. Is there anything that you would like to add about your experience integrating harm 
reduction and narcan training? 
 
Analysis: Theory 
In addition to looking for shared elements and commonalities among these subjects’ 
experiences, the analysis was alert for variations between them in order to explore the ways 
that overdose prevention training has been experienced differently among members of the 
subject population. The descriptive phenomenology approach was chosen because, in the 
absence of pre-existing research or analysis on this specific topic, it seemed most fitting to take 
an open-ended look at the conceptual landscape before committing to a more closed, 
quantitative methodology (Wojnar & Swanson, 2007). 
One central element of descriptive phenomenology is the process of suspending or 
bracketing prior beliefs or understandings that the investigator attaches to the phenomenon 
being studied. This is done in order to help them remain open to whatever meanings emerge 
from their subjects’ narratives, rather than forcing them to fit pre-existing theories or 
interpretations (Hycner, 1985). Bracketing must be an ongoing process throughout this type of 
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phenomenological investigation (Wojnar & Swanson, 2007). During the planning, 
interviewing, transcription, and analysis phases of this study, I maintained a reflective 
research journal in which I noted my own preconceptions and reactions concerning OEND, 
addiction treatment and recovery, ways that I might have influenced subjects’ responses, and 
any other issues that arose. 
 
Analysis: Process 
I digitally recorded the interviews. Immediately after each interview was complete, I 
used my research journal to record any significant information that might not have been 
captured on the audio recording—interruptions, time constraints, non-verbal communication, 
or deviations from the normal interview protocol. In addition, I made note of any of my own 
preconceptions or assumptions that may have come to light as a result of the interview. These 
journal entries were used to facilitate accurate transcription, to give a stronger sense of the 
meanings being conveyed, to improve my analysis of the narrative, and to ensure that 
bracketing remained an ongoing part of the process. 
Next I transcribed each interview verbatim, appending any notes taken after the 
interview. When each transcription was complete, I re-read it as a whole, re-listened to the 
original recording, and re-read it while listening to the recording. At this stage the intent was to 
get a general sense, or “gestalt” (Hycner, 1985) of the meaning(s) being conveyed. I continued 
to record my observations and impressions in my research journal, along with any of my own 
preconceptions or assumptions that may have come to light. 
Before starting the coding process, I entered the interview transcripts into the QDA 
Miner qualitative analysis package. I used this software to track and record codes, and to cross-
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reference them between interview transcripts. I coded the interview transcripts using an 
iterative process, first by open-coding to look for recurring and salient themes, and then by re-
coding them once I had developed a final list of coding categories (Hycner, 1985). As I 
created, combined, and eliminated categories I documented my decision-making process in my 
research journal. In doing this I focused on building a picture of how the subjects had 
experienced the process of incorporating naloxone distribution into their work. To do so, I 
used information that they provide explicitly (for instance, in response to questions 6 or 7), but 
I was sensitive to the language that they used when answering questions that addressed the 
topic less directly (such as 3, 4, 8 or 9). 
 
Analysis: Establishing trustworthiness 
Guba (1981) suggests that the “trustworthiness” of qualitative research be assessed in 
terms of how well it fulfills four criteria: truth value (i.e. how accurately it depicts the 
experience of its subjects), consistency (i.e. the extent to which the study’s results would be 
similar if it were repeated with other subjects in a similar setting), neutrality (i.e. the extent to 
which the study’s results are a function of its subjects’ experience, and not its researchers’), 
and applicability (i.e. how well its findings can be used to understand the experiences of other 
subjects in similar settings). Some strategies for establishing trustworthiness along the first 
three axes include member checking and peer debriefing (for truth value), maintaining an 
“auditable” diary of research decisions (for consistency), and reflexively documenting the 
bracketing process (for neutrality) (Guba, 1981; Hycner, 1985; Moore et al., 2002; Wojnar & 
Swanson, 2007). The fourth axis, applicability, may be “more the responsibility of the person 
wanting to transfer the findings to another situation or population than that of the researcher of 
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the original study”—the original researcher’s job being to provide enough descriptive detail to 
make this transfer possible (Krefting, 1991). 
I established this study’s truth value by debriefing and discussing category coding with 
a fellow researcher who has experience with qualitative research, in order to test my 
perceptions and open my interpretations to their questions (Guba, 1981; Hycner, 1985). The 
researcher in question was Jenn O'Neill, a licensed MSW and current PhD candidate at Lesley 
University. She has worked on qualitative research projects in the past, and was an AIDS 
Action Committee program manager during the time I was managing the Cambridge Needle 
Exchange. She served as interim supervisor for the needle exchange staff after my departure, 
and has a good deal of experience around opiate addiction and overdose. 
In addition, I conducted member checks with two of the ten subjects after their 
interviews have been transcribed and coded, in order to make sure that the themes I have 
derived from their interviews have faithfully captured the essence of their experience (Guba, 
1981; Hycner, 1985). In both cases, they reported that my summaries felt accurate to them. I 
established consistency and neutrality by maintaining a research journal to document the initial 
assumptions I had bracketed before beginning to conduct interviews, my subsequent reactions 
to the interviews themselves, and my decision-making process as I created, combined, and 
eliminated coding categories (Krefting, 1991). I also used this journal to document the 
feedback I received from peer researcher debriefings and member checks, and to track the 
ways I incorporated this feedback into my ongoing analysis. 
Finally, I made sure that it was clear at all stages that my intent was not to “evaluate” 
the programs whose staff I interviewed, nor to report the material details of how they have 
implemented overdose prevention training. I discussed this with each subject before beginning 
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the interview, and with other staff or supervisors with whom I spoke in the process of 
scheduling the interviews. I emphasized that all data included in my final analysis would be 
stripped of personal and program names, as well as any details that might identify a particular 
individual or program. 
When my analysis is finalized, I will present the results at a quarterly meeting of the 
Massachusetts OEND pilot program. I will also create a more streamlined write-up of my 
results that is suitable to be shared with the staff at the programs where my subjects work, or 
even with those working at other treatment programs with an interest in OEND. 
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CHAPTER VII 
RESULTS 
 
Ten subjects were interviewed. There were 7 women and 3 men, with 1-26 (average 9, 
median 5.5) years' experience working in the addiction field. The analysis process uncovered 4  
broad thematic domains in the interview subjects' experiences, each of which encompassed 
several parallel or contrasting themes: 
Thematic domain Themes 
What is overdose prevention training? Overdose prevention training is education 
Overdose prevention training is a narrative 
What is narcan? Narcan undermines recovery 
Narcan is part of a regular life routine 
Using a narcan kit is frightening 
Narcan saves lives 
What is harm reduction? Harm reduction means using drugs more safely 
Harm reduction is a means to an end 
What is the goal of treatment? The goal of treatment is abstinence 
The goal of treatment is survival 
The goal of treatment is up to the client 
 
When I have quoted them below, I have referred to them by number based on the order in which 
they were interviewed. 
 
Subjects' perception of overdose prevention trainings: Overdose prevention training is 
education 
This theme was the only one to be recorded at least once in every interview. Subjects 
generally mentioned it in a neutral, factual manner. 
Clients leave here with […] new information, upgraded information. -S10 
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I think that they appreciated, you know, the information. -S7 
However, two subjects returned to this theme again and again, in one case 18 times in the course 
of the interview. For them, the notion of overdose prevention training as education is of great 
significance. 
So I think the biggest thing is definitely the education the clients get. -S1, 
emphasis added 
 
And for one particular subject, this kind of education is seen as a societal good that transcends 
the narrow setting of the training sessions and their specific audience of addiction treatment 
program clients. 
And I think education is really important. And I'm glad to see, like I said, it's 
starting to come out on the TV and stuff like that. -S3 
 
We need a lot of education. You know, I talked to one of the police officers—we 
went to […] drug court graduation—and he says, you know, he's big on helping 
parents and educating them, which I think is wonderful. -S3 
 
Subjects' perception of overdose prevention trainings: Overdose prevention training is a 
narrative 
In contrast, this theme was not as widely recorded, and was not mentioned as often 
among those subjects who brought it up. However, it elicited detailed responses from a few 
subjects: 
We had one instance where [the client] left the facility, went right up to Dunkin 
Donuts, and used [a narcan kit]. Cause she found somebody in the bathroom. 
Right up the block. […] So that kinda hit hard for the people that were sitting in 
the group, it was nice. -S8, emphasis added 
 
[The trainer] really goes into detail, he's really good about: 'Let me get through all 
this information and then ask the questions after.' [...] Our clients, not that it's a 
bad thing, but some get very open, and they feel like they need to disclose 
information, so if he starts getting off track you have all these different 
conversations going on. -S8, emphasis added 
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The trainings are seen as proceeding along an educational “track,” but with the ever-present risk 
of being derailed by narrative and storytelling. While this can impede their educational function, 
it may also have positive value if it elicits an emotional response in the training participants. 
The notion of narrative overlaid on top of education was articulated more explicitly by 
another subject: 
I thought it was gonna be just: I'm gonna educate them, and it might be that I 
would be lecturing and they would be sitting, listening. And it's not like that at all. 
-S2, emphasis added 
 
They don't just sit like they're bored—they wanna talk about the losses that 
they've experienced in their lives and the people they knew that have overdosed. -
S2, emphasis added 
 
This repeated use of the word “just” suggests a contrast between the overdose prevention 
trainings' baseline educational component, and the narrative component that allows them to rise 
above that baseline (and the boredom that it entails). 
 
Subjects' perception of narcan itself: Narcan undermines recovery 
While this theme was recorded in a majority of the interviews, it was typically addressed 
obliquely and not as something that directly characterized the subjects' own current perception of 
narcan. For instance, for some subjects the idea that narcan might undermine recovery was 
relevant not primarily because they themselves thought it was true, but because they knew that 
other people did. 
It's interesting to bring [narcan] into a program where people aren't supposed to be 
using drugs. But some do. So a lot of patients were like, 'Well why are you giving 
me this? I don't use drugs anymore!' -S7 
 
I think the only negative thing is about, you know, just the perception of [narcan] 
and, you know, if it undermines their recovery or not. Some people think it might 
undermine it. -S1 
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Other subjects brought up this theme as something that had shaped their perception of narcan in 
the past, but that was not part of their current view. 
I did think [before being directly exposed to narcan trainings], 'I wonder if this 
isn't a good program, because does it encourage them to wanna go out and use 
opiates with their friends, knowing that they have a way to bring back or 
resuscitate a friend that...overdosed?' Now that I know more about it and I'm more 
educated, and I talk to the clients weekly about it I realize that it's saving lives. I 
no longer feel ambivalent about it, I feel strongly that it should be in the hands of 
those that use drugs, and it should be back at the homes of their families, and I 
completely—now that I know more about it—am a total advocate for it. -S2 
 
In fact, some of the subjects who mentioned that they had previously seen narcan as something 
that undermined recovery explicitly argued against this notion based on their current perception 
of narcan. 
At first […] you think you give [narcan] to 'em, you give them the okay to use. 
Well you know what, that's ridiculous. They're gonna use if they're gonna use. -S3 
 
When we first started [narcan trainings] back in 2008, some of my behavioral 
health staff were a little leery about it because they felt that we were enabling 
people to use by making narcan available. [“And how did those first few trainings 
go?”] They went fine because once they got the information they opened their 
eyes to the flipside of it. And it's not, you know, we're not trying to—I mean, 
people are gonna use no matter what. People aren't thinking 'Oh gee, it's okay for 
me to use now because I know there's narcan hangin' around.' -S4 
 
Subjects' perception of narcan itself: Narcan is part of a regular life routine 
When this theme appeared, it was often in very personal and immediate terms. In fact, 
nearly half of the interview subjects volunteered that they personally carried narcan with them 
outside of professional settings. 
I carry it in my glovebox all the time. -S9 
 
I even have narcan in my truck, I have narcan at my house. So if something 
happens I have narcan. -S10 
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For several subjects, this attitude carries over into their interactions with clients, who they also 
encourage to incorporate narcan into their lives whether or not they are actively using opioids. 
I tell the clients that […] 'if you can carry your drugs on you, why not carry the 
narcan?' -S1 
 
At one point, before we knew much about it we didn't allow it but we definitely 
allow it now and […] even if they don't wanna sign up we're kinda like 'You 
know, you might be at a stoplight, you could help somebody.' -S3 
 
Subjects' perception of narcan itself: Using a narcan kit is frightening 
This theme was also fairly common, appearing in half the interviews—generally among 
the subjects who did not report carrying narcan on their person outside of work. The main source 
of fear and anxiety tended to be the narcan kit itself. This was partly because it superficially 
resembles a syringe, which the subjects strongly associated with injection drug use. 
At first we were a little wary about it, cause it's new and it looks terrible. I mean it 
looks like a syringe. -S3 
 
My first thought was, 'Oh, it's a shot? We're not gonna give a heroin addict 
needles!' -S8 
 
In addition, some subjects saw the narcan kit as intimidating in its complexity, especially as they 
imagined trying to assemble it under the stressful conditions of a real overdose. 
[The narcan kit] looks a little intimidating I guess—put yourself in a situation, 
you know. I think it could be a lot easier to use. [“How so?”] I just feel like there's 
a lot of little things you have to do, you know, put certain parts here [...] I just feel 
like maybe in a situation with something going on like that, myself I'd be really 
shaky, and like, you know, trying to rush. And, you know, if it all came together 
already I just think it would be a lot quicker. But I've never had to use narcan on 
anyone. So I don't know really how it is in that situation, it's just me imagining. -
S6 
 
I think in the back of everybody's mind even including myself: 'God forbid I have 
to use it,' and 'I'm not confident using it,' and you know, fear is there. Because, 
number one, because of how you have to put 'em together and everything—you 
have the mechanics of what's involved before ever hittin' somebody up with it. -
S9 
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Not only is the narcan kit itself frightening due to its complexity and resemblance to a syringe, 
but several subjects were afraid that opioid users would react with anger or hostility after being 
given narcan. 
I also let 'em know that when you take them out of that overdose, they can be 
angry. And they can be violent so you have to be careful with that. -S3 
 
I have heard from clients before that when they're narcan-ed they get mad. 
Because their high goes away. -S6 
 
Subjects' perception of narcan itself: Narcan saves lives 
This theme appeared frequently and in most of the interviews. In some cases it referred to 
specific, concrete events. 
I saw a client on the outside and they told me, 'I died and like, I got brought back 
because of narcan.' -S5 
 
I had a client this morning who was here prior, he got the narcan here and before 
he left the program he said he ended up using with a friend, actually somebody 
that he met here. The friend overdosed, he had the narcan on him, hit him with 
narcan, saved his life. [...] I also shared a story with a client: I know this lady 
who's a social worker, who was leaving the gym and she seen this lady in the 
parking lot, shaking her husband and he was overdosing. She had narcan on her 
cause she was recently trained, she had a narcan in her car—hit him with narcan, 
saved his life. -S1 
 
At the narcan group yesterday when two clients raised their hands and said, 'Can I 
talk to you? That narcan you put in my suitcase, I saved my little brother.' -S2 
 
It was notable that even when they described narcan saving a particular life, the subjects were 
speaking about an overdose reversal that had been performed by a client, a friend, a co-worker, 
or a casual acquaintance—none of them described a situation in which they were the one to use 
narcan on an overdose victim. 
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Several other subjects emphasized this theme with no reference to a particular life-saving 
incident. For them narcan saves lives, and has the potential to continue saving lives, primarily in 
the abstract. 
[Narcan] saves lives. I mean it kinda speaks for itself, it's a no-brainer as far as 
I'm concerned: it saves lives. -S9 
 
While you're in the program, you're gonna get this training, and you're gonna get 
this medication that you can use to save someone, or someone can use to save 
you. -S7 
 
[Clients] leave here with the opportunity, even though they hope they don't have 
to use it, to save one of their peers' lives. -S10 
 
Subjects' perception of harm reduction: Harm reduction means using drugs more safely 
Although this was a less common theme, it did appear in over half the interviews. Some 
subjects acknowledged it indirectly, by providing examples of the kinds of advice they give to 
their clients: 
So I educate them as part of the narcan training, 'If this is not your last detox, and 
we hope to see you again—if this isn't it for you, there are things you can do to 
protect yourself from overdose before narcan might have to be used on you. Such 
as: don't use the amount that you used when you leave here. Use a tester shot. 
Know your drug dealer. Know that what you buy in the streets, what it is. Um, 
know and trust your drug dealer.' -S2 
 
I'll let them know, 'You know you should have the non-emergency line in there. 
That way you're not having police involvement. […] You know if you don't 
wanna call the police you can the ambulance instead. And if you do call the police 
you should just tell 'em that they're not breathing. That's it, you don't have to say 
anything else.' -S3 
 
They may not explicitly tie these examples to a broader philosophy of harm reduction, but that 
philosophy is implicit behind their attempts to help their clients use opioids more safely, by 
avoiding hazards such as overdose and contact with police officers. Other subjects expressed 
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their views on this theme more directly, with one of them even using the harm reduction trope of 
“meeting people where they are at”: 
I mean, I think that you have to meet people where they're at. So, some people 
aren't ready to stop using drugs, so if we can help them use in a safer way, then 
that's a step in the right direction. -S7 
 
[Harm reduction] is just integrated into [the work we do here] because we realize 
that, that people are gonna, people are gonna relapse—it's gonna happen. And our 
responsibility is to provide 'em with the tools and the resources they need, that if 
they do relapse, they don't die. -S4 
 
I just have come to see [harm reduction] as an integral part of what we do. I don't 
think we can do treatment without some degree of focus on, on harm reduction. -
S4, emphasis added 
 
Subjects' perception of harm reduction: Harm reduction is a means to an end 
This theme was even less common, but was interesting for being closely tied to the more 
direct and explicit endorsements of harm reduction described above. 
Sometimes we use, we use the harm reduction model with patients who need to 
come to the clinic, and so we kind of use the suboxone program as a way to get 
them in here for their other care. You know, for patients who are HIV positive, 
who need to see an infectious disease doctor, who need medication adherence 
counseling. So we'll kind of use, use the program to our benefit in that way. […] 
They wanna come for suboxone, cause they know they're gonna get the suboxone. 
They don't wanna come and see their infectious disease doctor, if they're not 
getting anything out of it. -S7 
 
I think harm reduction has its place even in abstinence-based treatment cause the 
reality is, people relapse and we need to keep them alive. And that's all we're 
trying to do at this point: keep 'em alive so we can get 'em into treatment. -S4, 
emphasis added 
 
Whether the end goal is a broad one like “get clients back into treatment” or a more specific one 
like “get clients connected to medical services that they wouldn't be motivated to seek out on 
their own,” here harm reduction is perceived as a tool that helps the subjects to achieve goals 
other than reducing the harm of opioid use. It was striking that this theme was most clearly 
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articulated by the same subjects who had most strongly expressed positive views of harm 
reduction in the broad, philosophical sense. 
 
Subjects' perception of addiction treatment: The goal of treatment is abstinence 
This was a common theme, and appeared in nearly all the interviews. In many cases the 
subjects acknowledged that they saw the goals of treatment as being complex and multi-faceted,  
but went on to assert that abstinence occupied a privileged place as the most important goal, or 
the most consistent, or the one that had to be in place before others could be addressed: 
I can't micromanage them but I can offer them all the support, aftercare in 
whatever community they live in—I will call veterans' groups if it's a veteran, I 
will call anyone I know with a contact anywhere to help them. Call someone at an 
AA meeting, 'Can you meet them at this group, cause they're afraid to go into a 
new group.' The best call I ever get is when someone calls back to say, 'Will you 
come see me get my [AA] medallion?' -S2, emphasis added 
 
In the back of my mind, I don't know if this is wrong or right, but I always have 
the ultimate goal of total abstinence [...] But if it's not their goal, it doesn't fly. But 
that's always the hope: to have a drug free, um, dependence free lifestyle. -S9, 
emphasis added 
 
I mean, the big picture is we want them to, you know, abstain from drugs and, 
kind of, become more active participants in the community. So we really 
encourage people, like when they're doing well, like, 'Well how about, you know, 
we start looking for employment, or volunteering, or, um...' You know, so those 
are our goals: for people to get clean, and then, like, be able to better themselves 
other ways. -S7, emphasis added 
 
In some cases the subjects so strongly saw abstinence as the primary goal of treatment that they 
discouraged clients from seeking out harm reduction resources that they felt might undermine it: 
I believe that if you're gonna be clean, be clean. But again, [suboxone] works for 
some people. Some people can do it and some people cannot. So...Again I'm open 
for anything that works for you. I would like you to try this road first, this clean 
road with nothing. Drop the suboxone, drop the methadone if you can—try that 
first, you know? -S3 
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I personally don't agree with teaching somebody, you know, different ways to, 
you know, shoot up or, you know, use needles like that. I don't agree with those 
things, I kinda feel like we're telling them, it's like an enabler I guess. -S6 
 
There are places we refer clients to that are harm reduction programs, that they 
aren't as strict and structured and they don't get urine tested. And some clients 
wanna go out cause they figure, 'Oh I'll use but not as much.' And I hesitate to 
send clients to some of those programs, because I feel like I'm setting them up for 
failure rather than success. -S2 
 
Subjects' perception of addiction treatment: The goal of treatment is survival 
Just over half the subjects saw the goal of addiction treatment as being, in part at least, to 
help clients stay alive even if they were not able to maintain abstinence: 
But if they don't have [access to clean syringes], they may die. And let's give them 
something to keep them safe for that day, the next couple days, until they realize 
what they need. -S8 
 
Keep 'em sober, keep 'em safe. Um, educate them. Let 'em know there's help, if 
they need it. Um, if they relapse it's not the end of the world. We can help. You 
know, come back, let us know, call us, tell us—we'll help you. They always worry 
that, you know, when they relapse we're mad at them. I'm like, 'We're not mad at 
you. You know? We wanna help you.' -S3 
 
For most subjects, this theme appeared alongside the previous one (that the goal of treatment was 
abstinence). Some alluded to a hierarchy of goals in which abstinence was ranked more highly 
(as described above), but for others the two goals coexisted without either one being prioritized. 
 
Subjects' perception of addiction treatment: The goal of treatment is up to the client 
Half of the interview subjects brought up this theme. As was the case with the previous 
theme, when the notion of client-set treatment goals was mentioned, it was usually contrasted 
with the subject's view that the proper goal of treatment was sobriety. 
In the back of my mind, I don't know if this is wrong or right, but I always have 
the ultimate goal of total abstinence [...] But if it's not their goal, it doesn't fly. But 
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that's always the hope: to have a drug free, um, dependence free lifestyle. -S9, 
emphasis added 
 
We're very client-centered in our treatment. So...it's really about their goals, not 
ours. Um...and what they're looking for. And the needs of the population that we 
serve are so complicated, so much more complicated than they used to be years 
ago. [...] I mean there's just like a whole laundry list of things, and the challenge 
in treatment and what we want to help clients do is to learn to prioritize what 
comes first, and tackle each piece step by step. Obviously we wanna encourage 
them to be abstinent but we can't make that decision for them, so it's really about, 
our treatment focus is really about personal empowerment. -S4, emphasis added 
 
I think they're just different levels [...] Teaching someone to, you know, clean 
their needles is different, you know, that person's just at a different level than 
someone being on methadone or suboxone, ready to stop using drugs altogether. -
S7 
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CHAPTER VIII 
DISCUSSION 
 
What is overdose prevention training? 
Although they took place in a range of settings, involving different client populations and 
staff with widely varying degrees of experience, the overdose prevention trainings themselves 
were consistently experienced as an educational exercise first and foremost. This is not 
surprising, given the trainers' need to convey information and key concepts within the time and 
logistical constraints of treatment programs such as these. However, some subjects also 
experienced these training sessions as a space where clients and staff shared and processed their 
experiences surviving overdose, rescuing others from overdose, and losing friends and loved 
ones to overdose. Some subjects felt tension between the trainings' educational format and their 
clients' desire for narrative communication and emotional catharsis. However, even when they 
described this as filling a need that education alone could not, they did not discount the value of 
education. Rather, education was seen as the foundation of overdose training, and narrative as 
the element that strengthened and filled gaps in that foundation. 
 
What is narcan? 
Subjects perceived narcan itself in many ways, some of which appeared to be at odds 
with each other. For instance, the narcan kits themselves were intimidating and complex to 
many, and the process of using them was imagined to be frightening, but narcan was also seen as 
something that should be part of everyday life—carried not just by active injection drug users, 
but by anyone who might come across an overdose in any public location. Narcan is seen as life-
saving, but also as something that can easily be misconceived as promoting drug use. 
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Significantly, compared to the other themes found in this study, the subjects experienced narcan 
through a lens of external and indirect factors—memories of their own past opinions, 
assessments of other people’s beliefs, hypothetical fears, and accounts of other people’s 
experiences. Their own direct experiences with the kits themselves, with overdose reversals or as 
overdose victims, were presented as a relatively small piece of the picture. Perhaps this theme’s 
inconsistencies are a result of this lack of firsthand experience administering or receiving narcan 
in an actual overdose situation. 
 
What is harm reduction? 
When the interviewer mentioned a range of harm reduction strategies, some subjects 
responded in broad emotional terms, with little or no emphasis on their particular experience or 
reasoning. This general emotional reaction could be negative: 
I am not a fan of it. –S5 
 
I mean I just feel like when you're teaching them things like that, we're just 
showing them new ways, you know, do you understand what I'm saying? […] I 
don't even know. I just, I don't know—I'm just not a fan of things like that. I feel 
those are negative things I guess. –S6, emphasis added 
 
But it could also be positive: 
[“What sorts of differences would you see between these different types of harm 
reduction strategies?”] I really don't see any differences, I'm seeing a lot of 
similarities. I mean, it's all like I said: it's all a form of reducing harm. It's a 
beautiful thing—nobody's out to hurt anybody, we're all trying to help keep folks 
alive. So it's a common bond and that's what stands out for me, is not—I don't see 
any differences. –S9, emphasis added 
 
While some subjects painted harm reduction with a broad brush as “negative things” or 
“a beautiful thing,” others recounted a more specific experience of the concept as it related to 
their work. They understood and implemented harm reduction as a way to help their clients 
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remain safe (from physical harm, from incarceration) while they continued to actively use drugs. 
Even when this philosophy was not explicitly articulated, it was clearly implicit in the 
interactions that these subjects described having with their clients, both in and outside of 
overdose prevention training sessions. Keeping clients safe and alive was presented as the self-
evident end goal of harm reduction, but sometimes it also served as a way to accomplish 
additional goals, such as getting clients back into treatment or connecting them with medical 
care. In other words, they experienced harm reduction as an integrated part of treatment, rather 
than as a discrete safety-providing mechanism that could be added or subtracted from their work. 
 
What is the goal of treatment? 
Clients’ abstinence from drug use was strongly felt to be the primary goal of treatment. 
However, many subjects also acknowledged other goals, such as helping clients to remain safe 
and alive, or supporting goals that the clients set for themselves. When subjects felt that these 
goals were in conflict, abstinence was often the priority. Even when they had otherwise 
expressed support for harm reduction, they did not see it as something that could be weighed 
against abstinence—the conflict was essentially one-sided, with abstinence the a priori winner. In 
a sense, they did not experience the conflict between goals as a “conflict” at all, since the 
outcome was a foregone conclusion. However, there were times when the goals of treatment 
were seen as less hierarchical, with clients’ safety, sobriety, and self-determination as mutually 
complimentary rather than opposed to one another. To some extent, this perspective was more 
characteristic of subjects who had a more integrated view of the relationship between treatment 
and harm reduction (see “What is harm reduction?”, above), but the two themes did not overlap 
exactly. 
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CHAPTER IX 
LIMITATIONS 
 
When assembling a sample population, my original intention was to strike a balance 
between subjects who came from programs that seemed to be supportive and receptive to 
OEND, and those who came from programs for whom OEND had not been as smooth a fit—
in other words, to sample purposively in order to capture a range of perspectives. This 
intention was to be implemented by asking the OOPPP contacts to place each of their partner 
programs (i.e. the sites where they conducted OEND training sessions, and from whose staff 
my sample population would be drawn) in one of the three following categories: 
1. The program requested OEND and was supportive of OOPPP staff 
2. The program did not actively request OEND but was not resistant to it 
3. OOPPP staff had to reach out to the program several times before they agreed to 
host OEND, and/or found it challenging to collaborate with them 
When I reached out to potential subjects, I attempted to include at least 3 from programs that 
were rated “1” on the scale above, and at least 3 that were rated “3.” Unfortunately this proved 
to be impossible, because a majority of the contacts I was given by OOPPP fell under the first 
category, while only a small minority (3 total) fell under the third. The final 10-subject sample 
included 7 subjects from the first category, 1 from the second, and 2 from the third. 
Technically, this is very close to my stated goal: if a single subject from the first or second 
category was replaced by one from the third, the final sample would have met the criteria 
established at the outset. However, it is difficult not to see this sample as strongly skewed 
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towards programs supportive of OEND, according to the spirit as well as the letter of my 
sampling strategy. 
I suspect this may have been caused in part by self-selection, whereby programs whose 
leadership and/or institutional culture were most supportive of OEND were more likely to host 
trainings more often and build relationships with OOPPP staff, which led them to be 
disproportionately represented in my pool of potential subjects. Conversely, programs that 
resisted OEND may have self-selected out of that potential subject pool by hosting trainings 
irregularly or infrequently, and failing to establish the kinds of relationships that would have 
led my OOPPP contacts to suggest them as interview subjects. It is also possible that programs 
which found OEND challenging for logistical reasons (such as understaffing or staff turnover) 
found participation in this study challenging for the same reasons—while no programs declined 
to participate outright, there were several with whom I was unable to make contact after 
repeated attempts, or with whom I was not able to schedule and conduct an interview even 
after establishing contact. In fact, this was the case with the one “challenging” program whose 
staff I did not interview. Finally, although I did my best to make it clear that I did not intend to 
judge or evaluate the programs they were putting me in touch with, it is possible that my 
OOPPP informants were reluctant to place an arguably negative label like “challenging” on a 
program with which they were collaborating. This could have resulted in a programs being 
described as more supportive than they actually were, and made it difficult to assess how well 
my purposive sampling protocol had actually been implemented. 
In hindsight, there are several strategies that might have mitigated the above limitations 
of my study. For instance: I could have recruited subjects from programs that had previously 
hosted OEND but were no longer doing so, in the hopes that this would give me a larger pool 
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of potential subjects from challenging or OEND-resisting programs. I could have provided 
individual- and/or program-level incentives in order to make participation more attractive to 
programs facing staffing or organizational challenges. And finally, I could have framed my 
sampling strategy differently, in order to avoid making key informants feel less like they were 
passing judgment on their collaborators. Unfortunately, it was not possible to employ any of 
these strategies “on the fly” as I was conducting this study—the first would have represented a 
significant change in the study, the second would have required resources that were not at my 
disposal, and the third would not have been effective once my informants’ perception was 
colored by the (perhaps loaded) way the question was initially asked. 
 
 
 39 
CHAPTER X 
CONCLUSIONS 
 
My first research question was “Was the integration of OEND into recovery-oriented 
programs disruptive or controversial?” Based on analysis of these interviews, I have concluded 
that these subjects have not experienced the introduction of OEND as disruptive. On the few 
occasions when they did mention disruption, the subjects felt that their clients’ need for catharsis 
and personal engagement were not being met by the trainings’ over-emphasis on strictly 
educational content. They did not experience this as a failure of the trainings (or trainers), or as 
poor conduct by their clients, but rather as an opportunity to enhance the trainings by 
strengthening their narrative component. Future OEND programs may benefit from explicitly 
acknowledging the importance of narrative, and creating space for staff and clients to share 
personal experiences and real-world examples to illustrate and complement their more traditional 
educational content. 
The subjects also did not experience OEND training as a controversial topic. When they 
did allude to controversy, they situated it outside of their own current experience—either a thing 
of the past, or a characteristic of other people’s beliefs. These controversies were resolved by the 
subjects and/or their coworkers gaining a greater understanding of the issues around narcan and 
overdose, or by conversations in which the subjects successfully defended OEND to skeptics. 
This suggests that even it situations where OEND seems controversial in the abstract, the 
controversy may dissipate once staff members have gained a better understanding of the 
underlying issues, and have seen the training and tools provided firsthand. Communities and 
programs that are considering the adoption of OEND can take comfort in the fact that whatever 
controversy they initially face is unlikely to be deep-seated or long-lasting. 
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My second research question, however, was more challenging: “Did recovery-oriented 
program staff find it difficult to reconcile the harm reduction philosophy underlying OEND with 
their personal and organizational philosophies around substance use and recovery?” Although 
they overwhelmingly supported OEND itself, and tended to speak positively of “harm reduction” 
in a non-specific sense, many subjects engaged with harm reduction (as a philosophy, but also as 
a set of strategies) in fairly limited ways, especially when it threatened to encroach on the notion 
of abstinence as the primary goal of treatment. In these situations, they tended to unilaterally 
prioritize abstinence. Some experienced this as an emotional conflict, and expressed negative 
views of harm reduction in this context; others simply took for granted that harm reduction 
would give way to abstinence, but did not hold any negative feelings towards it. In both cases, it 
seems that these subjects did indeed find it difficult to reconcile harm reduction with their 
personal beliefs about abstinence—or perhaps, that they did not feel as if the two needed to be 
“reconciled” at all, since it was a foregone conclusion that abstinence-oriented philosophies and 
practices would trump harm reduction. 
For advocates of harm reduction, this finding has both positive and negative implications. 
On the one hand, it appears that OEND can be integrated into environments that are not receptive 
to harm reduction in a broader sense. In other words, OEND is an effective and widely 
acceptable way to reduce overdose fatalities now, without having to wait for a resolution of the 
larger philosophical questions around harm reduction. On the other hand, in spite of its 
effectiveness, OEND may not be a particularly good way to introduce harm reduction into 
settings that had previously resisted it—precisely because OEND is so concretely effective and 
uncontroversial, it is easy for staff to mentally separate it from the more abstract and challenging 
issues that make harm reduction unpalatable to them. If “bringing harm reduction into recovery-
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oriented settings” is seen as a secondary goal of OEND, there may remain work to be done even 
if OEND is successfully implemented on a wide scale. Indeed, it might be useful to further 
investigate the way other harm reduction strategies are understood and experienced in settings 
like these, in order to learn whether it is realistic to expect that resistance to them can eventually 
be overcome the way resistance to narcan was in this study (i.e. by exposure and education), or 
whether the relatively rapidly acceptance of narcan should be seen as a special case. In other 
words: is the growing acceptance of narcan something that can eventually be replicated with 
other harm reduction strategies, and if so what will need to be done in order to make that happen 
more readily than it has among my subjects? 
Although some subjects experienced harm reduction (aside from OEND) mainly in the 
abstract, others did describe a work environment where harm reduction had been reconciled with 
abstinence-based treatment philosophies. For them, harm reduction was more concrete than it 
was for the subjects mentioned above, with more clear and explicit connections to the ways they 
helped their clients. For instance, integrating harm reduction into their workplace might mean 
focusing on client-selected goals other than abstinence, or helping clients to more safely use 
drugs when they were not prepared to stop—in other words, they sometimes prioritized harm 
reduction over abstinence. They did not experience this as a negative thing, even though they felt 
that ultimately, abstinence remained at the core of their personal and organizational philosophies. 
Harm reduction was not viewed with suspicion, or mere tolerance, or as something that was only 
applicable in specific limited circumstances. Rather it was an integral part of their treatment  
landscape—a landscape that was too complex to be explored through a strictly abstinence-based 
lens. In the words of one subject: 
I just have come to see [harm reduction] as an integral part of what we do. I don't 
think we can do treatment without some degree of focus on harm reduction. -S4 
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Because this study focused on its subjects' experiences, rather than issues of cause and effect, it 
does not show how these programs' acceptance of harm reduction was or was not a result of their 
implementation of OEND. Perhaps a future study could focus on this issue more specifically, and 
attempt to establish whether there are lessons that can be learned from programs like these. A 
prospective study might be especially useful here, in order to learn whether in addition to its 
primary goal of reducing overdose fatalities, OEND has had a positive effect on some program 
staff's willingness and ability to embrace other harm reduction strategies. If this does turn out to 
be the case, it would be very interesting to explore what makes these programs and staff different 
from the ones mentioned earlier, for whom the acceptance of OEND did not lead to a broader 
integration of harm reduction into the workplace. 
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